Business
Syngene International extends long-term research collaboration with Bristol Myers Squibb until 2035
Syngene International, a global contract research, development, and manufacturing organization (CRDMO), today announced the extension of its long-standing strategic collaboration with Bristol Myers Squibb through 2035. The expanded agreement broadens the scope of integrated services across the drug development lifecycle spanning discovery (chemistry, biology, drug metabolism and pharmacokinetics), translational sciences, pharmaceutical development and manufacturing, clinical trials, data and inf
About this update from Bristol-myers Squibb Company
[{"type":"text","content":"BENGALURU, India, Jan. 21, 2026 /PRNewswire/ -- Syngene International, a global contract research, development, and manufacturing organization (CRDMO), today announced the extension of its long-standing strategic collaboration with Bristol Myers Squibb through 2035. The expanded agreement broadens the scope of integrated services across the drug development lifecycle spanning discovery (chemistry, biology, drug metabolism and pharmacokinetics), translational sciences, pharmaceutical development and manufacturing, clinical trials, data and information technology services to enable seamless progression from research to commercialization. The expansion of this collaboration marks the next phase of growth, reinforcing Syngene's position as a strategic partner delivering integrated, end-to-end scientific and manufacturing solutions.","length":848,"tagName":"p"},{"type":"image","alt":" ","displaySize":"","headline":null,"caption":" ","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":98,"url":"https://media.zenfs.com/en/prnewswire.com/40f980b663509f5a232e1394ee96431f"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/5jAGZ931wFIaWSrAO5lYsA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTE3MztjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/40f980b663509f5a232e1394ee96431f","width":400,"height":98}}},{"type":"text","content":"Peter Bains, Managing Director and CEO, Syngene International Ltd., said, "Our collaboration with Bristol Myers Squibb, which now spans more than 25 years, is anchored in scientific excellence, operational reliability, and a shared commitment to advancing innovative therapies. The agreement to extend this partnership through 2035 enables us to plan together for the future in terms of building new capabilities and infrastructure with a decade long horizon. Taking a long-term perspective is a key feature of our partnership which adds strategic value to both companies. We look forward to supporting BMS with their next wave of discovery, development, and manufacturing programs that have the potential to improve patient outcomes worldwide." ","length":755,"tagName":"p"},{"type":"text","content":"Payal Sheth, Senior Vice President, Therapeutic Discovery Sciences, Bristol Myers Squibb, said, "At Bristol Myers Squibb, everything we do begins with patients. We greatly valu...